alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a
Company profile
Ticker
ALVO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Alvotech Lux Holdings S.A.S.
SEC CIK
Corporate docs
IRS number
981629342
ALVO stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
25 Apr 24
6-K
Current report (foreign)
19 Apr 24
6-K
Current report (foreign)
16 Apr 24
6-K
Alvotech Announces Increase in Number of Own Shares
22 Mar 24
20-F
2023 FY
Annual report (foreign)
20 Mar 24
6-K
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
20 Mar 24
6-K
Alvotech Appoints Interim Chief Quality Officer
1 Mar 24
6-K
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
26 Feb 24
6-K
Current report (foreign)
23 Feb 24
6-K
Current report (foreign)
15 Feb 24
Latest ownership filings
SC 13G/A
Oaktree Acquisition Holdings II, L.P.
14 Feb 24
SC 13G
Oaktree Acquisition Holdings II, L.P.
14 Feb 23
SC 13D/A
Celtic Holdings SCA
18 Nov 22
SC 13D/A
Aztiq Pharma Partners S.a r.l.
18 Jul 22
SC 13D/A
Celtic Holdings SCA
15 Jul 22
SC 13D
Aztiq Pharma Partners S.a r.l.
5 Jul 22
SC 13D
Celtic Holdings SCA
27 Jun 22
SC 13G
YA II PN, Ltd.
22 Jun 22
Financial summary
Quarter (USD) | Dec 22 | Jun 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Jun 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q3 2023
94.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 4 |
Closed positions | 15 |
Increased positions | 4 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 160.92 bn |
Total shares | 250.83 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Aztiq Pharma Partners S.a r.l. | 101.15 mm | $702.98 mm |
Celtic Holdings SCA | 90.01 mm | $540.93 mm |
YA II PN | 27.04 mm | $0.00 |
Oaktree Acquisition Holdings II | 14.87 mm | $0.00 |
Oaktree Capital Management | 5.04 mm | $46.00 bn |
Bracebridge Capital | 4.36 mm | $39.77 bn |
Vanguard | 2.88 mm | $26.28 bn |
Littlejohn & Co | 1.13 mm | $10.33 bn |
Sculptor Capital | 1.09 mm | $9.95 bn |
Temasek | 1.00 mm | $9.12 bn |
News
Alvotech, Teva Announce US FDA Approval Of SELARSDI, Biosimilar To Stelara
16 Apr 24
Alvotech Receives FDA Approval For Selarsdi For Moderate To Severe Plaque Psoriasis
16 Apr 24
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
25 Mar 24
Alvotech Announces Increased The Company's Share Capital By An Amount Of $130K By Issuing 13M Ordinary Shares
22 Mar 24
Barclays Maintains Overweight on Alvotech, Raises Price Target to $20
22 Mar 24
Press releases
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30 Apr 24
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30 Apr 24
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24 Apr 24
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16 Apr 24
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
3 Apr 24